Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.67 |
| ▸ | PDE5A | O76074 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17800034 | 0.90 | SLC6A3 (0.62) | SLC6A3PDE5AAPP | |
| SCHEMBL17800059 | 0.88 | SLC6A3 (0.56) | SLC6A3PDE5AAPPPTGS1TBXAS1 | |
| SCHEMBL17799833 | 0.87 | SLC6A3 (0.62) | SLC6A3PDE5AAPPGBA1MEN1 | |
| SCHEMBL17803691 | 0.84 | SLC6A3 (0.62) | SLC6A3APPALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL17799996 | 0.81 | SLC6A3 (0.66) | SLC6A3PDE5AAPPMEN1KMT2A | |
| SCHEMBL17800894 | 0.80 | SLC6A3 (1.00) | SLC6A3MEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL17800935 | 0.78 | SLC6A3 (1.00) | SLC6A3 | |
| SCHEMBL17799967 | 0.77 | SLC6A3 (0.68) | SLC6A3PDE5AGBA1MEN1KMT2A | |
| SCHEMBL17799848 | 0.77 | APP (0.63) | SLC6A3PDE5AAPPMAPT | |
| SCHEMBL17800067 | 0.76 | SLC6A3 (0.60) | SLC6A3PDE5AAPPMAPK1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087148-B2 | Quinazolines as biogenic amine transport modulators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTH (US) | 2018-10-02 | — | — | US | disclosed |
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3226867-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | Ananthan, Subramaniam (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3226868-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | Ananthan, Subramaniam (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| US-20160159751-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090299-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087148-B2 | Quinazolines as biogenic amine transport modulators | SLC18A2, SLC6A2, SLC6A3 | SLC6A3 3/4885PDE5A 711/4885APP 4050/4885 |
| US-20160159751-A1 | NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A3 3/4885PDE5A 949/4885APP 4072/4885 |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A3 3/4885PDE5A 836/4885APP 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.